CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
saracatinib +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00735917
NCT00735917Phase 2Completed
CompareCT.gov

A Phase II Trial of AZD0530 in Previously Treated Metastatic Pancreas Cancer

National Cancer Institute (NCI)·interventional·Posted Aug 15, 2008·Updated Apr 2, 2019

In Brief

A Phase 2 clinical trial evaluating saracatinib, pharmacogenomic studies, and 4 other interventions for Adenocarcinoma of the Pancreas and 2 related conditions. Completed, enrolled 19 participants across 9 sites in 3 countries.

Detailed Summary

This phase II trial is studying how well saracatinib works in treating patients with previously treated metastatic pancreatic cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
CountriesAustralia, Singapore, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 15, 2008
Enrollment StartOct 1, 2008
Primary CompletionApr 1, 2011
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.9 years ago

Interventions

saracatinibdrug

Given PO

pharmacogenomic studiesother

Optional correlative studies

pharmacological studyother

Optional correlative studies

positron emission tomographyprocedure

Optional correlative studies

fludeoxyglucose F 18radiation

Optional correlative studies

laboratory biomarker analysisother

Optional correlative studies